Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2020-04-17 AGM Information
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB" which translates to 'Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB'. It details the date, time, location, registration procedures, proposed agenda items (including changes to the board and remuneration), and voting rights for an upcoming shareholder meeting. This content directly corresponds to the purpose of an AGM notice, which is to convene shareholders for voting and discussion. Although it is a notice, the content is specific to the meeting itself, making 'AGM-R' (AGM Information) the most appropriate classification, as it contains the core information for the meeting, rather than just announcing the publication of a report (RPA).
2020-04-17 Swedish
Oasmias valberedning föreslår förändringar i styrelsen
Board/Management Information Classification · 99% confidence The document is a press release titled "Oasmias valberedning föreslår förändringar i styrelsen" (Oasmia's nomination committee proposes changes to the board). It details proposed changes to the Board of Directors, including the nomination of a new chairman and a new member, and the departure of two current members, to be decided at an Extraordinary General Meeting (EGM). This content directly relates to the composition and changes within the company's governing body (Board of Directors). According to the definitions, 'Board/Management Information' (MANG) covers the announcement of changes in the company's board of directors or senior management. Although an EGM is mentioned, the core subject is the board composition proposal, making MANG the most accurate fit over AGM-R or DVA (which deals with voting results). The document is short and appears to be an announcement, but the subject matter is specific enough to classify it as MANG rather than the general fallback RNS.
2020-04-17 Swedish
Oasmia Nomination Committee suggest changes in the Board of Directors
Board/Management Information Classification · 98% confidence The document explicitly announces proposed changes to the company's Board of Directors, including the nomination of a new Chairman and new members, and the departure of existing members. This directly aligns with the definition of 'Board/Management Information' (MANG). Although it mentions an upcoming EGM, the core content is the management/board change proposal, not the voting results (DVA) or the full proxy materials (PSI). The document length is relatively short (3807 chars) and it is an announcement regarding a future event, but the subject matter is specific enough to warrant the MANG classification over the general 'RPA' or 'RNS' fallback.
2020-04-17 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for Oasmia Pharmaceutical AB, covering the period from May 1, 2019, to January 31, 2020. It contains comprehensive financial statements, including income statements, management commentary, and operational updates for the third quarter. It is a substantive financial report rather than an announcement or a certification, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-03-27 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim report' for Oasmia Pharmaceutical AB covering the period from May 1, 2019, to January 31, 2020. It contains detailed financial statements (consolidated income statement), management commentary, operational updates, and legal disclosures. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-03-27 English
Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea® with an upfront payment of USD 20 million, milestone payments with a potential of up to USD 678 million and
Regulatory Filings Classification · 95% confidence The document text is a press release dated March 25, 2020, announcing a major global strategic partnership between Oasmia Pharmaceutical AB and Elevar Therapeutics regarding the commercialization of the drug Apealea®. It details upfront payments, milestone potential, and royalty structures. This type of announcement, which details significant business transactions, financing arrangements, or strategic agreements, most closely aligns with the 'Capital/Financing Update' (CAP) category, as it involves a large financial deal (USD 20M upfront + potential milestones). While it is a press release, the core subject matter is a major financing/commercialization deal, making CAP more specific than the general 'RNS' fallback. It is not a full 10-K, an earnings release (ER), or a proxy statement (DEF 14A). Given the nature of the deal involving significant capital exchange and commercial rights, CAP is the best fit.
2020-03-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.